We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Asthma and risk of myelodysplastic syndromes: a population-based cohort study.
- Authors
Frederiksen, Henrik; Farkas, Dóra Körmendiné; Horváth-Puhó, Erzsébet; Nørgaard, Jan M; Nørgaard, Mette; Sørensen, Henrik T; Farkas, Dóra Körmendiné; Horváth-Puhó, Erzsébet; Nørgaard, Jan M; Nørgaard, Mette; Sørensen, Henrik T
- Abstract
<bold>Background: </bold>Risk factors for the development of myelodysplastic syndromes (MDS) include age, exposure to ionising radiation, and cytotoxic drug treatment. Recently, asthma also has been suggested as a risk factor for MDS.<bold>Methods: </bold>We undertook this nationwide population-based cohort study on patients with a first-time hospital-based asthma diagnosis during 2002-2013 and followed them for the development of MDS/chronic myelomonocytic leukaemia (CMML).<bold>Results: </bold>We identified 75 995 patients with incident asthma and no previous MDS/CMML diagnosis. Seventy-eight patients subsequently developed MDS and nine patients developed CMML during 402 892 person-years. The cumulative risks of developing MDS/CMML among asthma patients were 0.02% (95% CI: 0.01-0.04%) and 0.07% (95% CI: 0.05-0.09%) during the first year and the first five years of follow-up, respectively. The standardised incidence ratio of MDS/CMML among asthma patients overall was 1.6 (95% CI: 1.3-2.0) with little variation across subgroups.<bold>Conclusions: </bold>Asthma may be a risk factor for the development of MDS/CMML.
- Subjects
MYELODYSPLASTIC syndromes; ASTHMA; CONFIDENCE intervals; LONGITUDINAL method; CHRONIC myeloid leukemia; DISEASE incidence; DISEASE risk factors
- Publication
British Journal of Cancer, 2017, Vol 116, Issue 1, p100
- ISSN
0007-0920
- Publication type
journal article
- DOI
10.1038/bjc.2016.389